Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2017 2
2018 1
2021 1
2022 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription.
Gorodetska I, Offermann A, Püschel J, Lukiyanchuk V, Gaete D, Kurzyukova A, Freytag V, Haider MT, Fjeldbo CS, Di Gaetano S, Schwarz FM, Patil S, Borkowetz A, Erb HHH, Baniahmad A, Mircetic J, Lyng H, Löck S, Linge A, Lange T, Knopf F, Wielockx B, Krause M, Perner S, Dubrovska A. Gorodetska I, et al. Among authors: di gaetano s. Theranostics. 2024 Jan 1;14(2):714-737. doi: 10.7150/thno.88057. eCollection 2024. Theranostics. 2024. PMID: 38169509 Free PMC article.
Nuclear imaging in cancer theranostics.
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M. Del Vecchio S, et al. Among authors: zannetti a. Q J Nucl Med Mol Imaging. 2007 Jun;51(2):152-63. Q J Nucl Med Mol Imaging. 2007. PMID: 17420716 Free article. Review.
From an historical perspective, the concepts underlying the theranostic strategy are well known in nuclear medicine and constituted the basis of many nuclear imaging procedures currently used in clinical practice. ...Here, we review the contribution that non-invasiv …
From an historical perspective, the concepts underlying the theranostic strategy are well known in nuclear medicine and consti …
Optimization of Short RNA Aptamers for TNBC Cell Targeting.
Camorani S, d'Argenio A, Agnello L, Nilo R, Zannetti A, Ibarra LE, Fedele M, Cerchia L. Camorani S, et al. Among authors: zannetti a. Int J Mol Sci. 2022 Mar 23;23(7):3511. doi: 10.3390/ijms23073511. Int J Mol Sci. 2022. PMID: 35408872 Free PMC article.
Chemical Modification for Proteolytic Stabilization of the Selective αvβ3 Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells.
Comegna D, Zannetti A, Del Gatto A, de Paola I, Russo L, Di Gaetano S, Liguoro A, Capasso D, Saviano M, Zaccaro L. Comegna D, et al. Among authors: zaccaro l, zannetti a, del gatto a, di gaetano s. J Med Chem. 2017 Dec 14;60(23):9874-9884. doi: 10.1021/acs.jmedchem.7b01590. Epub 2017 Dec 4. J Med Chem. 2017. PMID: 29144748
Herein, we report the synthesis and biological characterization of the new peptide psiRGDechi as the first step toward novel-targeted theranostics in melanoma. This pseudopeptide is designed from our previously reported RGDechi peptide, known to bind selectively alpha(v)be …
Herein, we report the synthesis and biological characterization of the new peptide psiRGDechi as the first step toward novel-targeted the …
Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.
Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A. Camorani S, et al. Among authors: zannetti a. Theranostics. 2017 Aug 22;7(14):3595-3607. doi: 10.7150/thno.18974. eCollection 2017. Theranostics. 2017. PMID: 28912898 Free PMC article.